drugset / Trial / NCT02303509
Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject
RandomizedCrossoverDouble-blindBasic science
Summary
To evaluate the safety and tolerability of UCB5857. Part 1 of the study explores single doses of the drug. Part 2 of the study explores giving the drug every day for 14 days. The study uses healthy and psoriasis subjects.
Timeline
- Start
- 2013-08
- Primary completion
- 2014-02
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | seletalisib | Small molecule | 1 mg | Oral |
| Subject | seletalisib | Small molecule | 5 mg | Oral |
| Subject | seletalisib | Small molecule | 8 mg | Oral |
| Subject | seletalisib | Small molecule | 10 mg | Oral |
| Subject | seletalisib | Small molecule | 15 mg | Oral |